Myriad Genetics Inc
MYGNMyriad Genetics Inc is a biotechnology company specializing in molecular diagnostics and genetic testing. It develops and commercializes tests that assess risk for various diseases, including cancer, women's health conditions, and other hereditary disorders. The company focuses on personalized medicine solutions to help guide clinical decision-making and improve patient outcomes.
Company News
The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% mar...
Myriad Genetics announced a partnership with Netflix actress Jackie Tohn to promote awareness about hereditary cancer testing through the MyRisk® Hereditary Cancer Test. Tohn discovered she carried a BRCA1 gene variant and underwent preventive measures after learning she had an 85% risk of breast cancer and 65% risk of ovarian cancer. The MyRisk...
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding health...
Myriad Genetics announced the advancement of its Precise MRD product toward a March 2026 launch, supported by new breast and colorectal cancer study data demonstrating ultrasensitive ctDNA detection. The company also released select preliminary fourth quarter and full year 2025 financial results and provided full year 2026 financial guidance.
The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and p...
